	US 12,201,719 B2
	Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
Brian Czerniecki, Tampa, FL (US); Krithika N. Kodumudi, Tampa, FL (US); and Elizabeth Evans, Bloomfield, NY (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc. (A Florida Non-Profit Corporation), Tampa, FL (US); and VACCINEX, INC., Rochester, NY (US)
Filed by H. Lee Moffitt Cancer Center and Research Institute, Inc. (A Florida Non-Profit Corporation), Tampa, FL (US); and VACCINEX, INC., Rochester, NY (US)
Filed on Apr. 27, 2023, as Appl. No. 18/307,920.
Application 18/307,920 is a division of application No. 16/906,713, filed on Jun. 19, 2020, granted, now 11,660,330.
Claims priority of provisional application 62/865,027, filed on Jun. 21, 2019.
Prior Publication US 2024/0050544 A1, Feb. 15, 2024
Int. Cl. A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01)

CPC A61K 9/0019 (2013.01) [A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/464402 (2023.05); A61K 39/464406 (2023.05); A61K 2035/122 (2013.01); A61K 2239/31 (2023.05); A61K 2239/49 (2023.05)]

14 Claims

1. A method of treating a human epidermal growth factor 2 (HER2) positive cancer in a subject comprising administering to the subject an anti-cancer combination therapy comprising at least one dendritic cell pulsed with a HER2 oncodriver administered intratumorally and at least one immunoregulatory molecule inhibitor comprising an antibody or an antigen-binding fragment thereof that binds specifically to Semaphorin 4D (SEMA4D), wherein said immunoregulatory molecule inhibitor is administered systemically; and wherein administration of the combination therapy results in tumor shrinkage of injected and non-injected tumors.